PDF(Pubmed)
Abstract：
UNASSIGNED: To compare the efficacy of intravenous administration of nalbuphine at different time points for postoperative analgesia and sedation in adenotonsillectomized children.
UNASSIGNED: Patients with obstructive sleep apnea syndrome scheduled for adenotonsillectomy were randomly divided into group A (patients received intravenous nalbuphine 0.2 mg/kg before anesthesia induction), group B (patients received intravenous nalbuphine 0.2 mg/kg 10 min before the end of surgery), and group C (patients did not receive nalbuphine injection). The time points for measuring outcomes were before anesthesia induction (T0), extubation (T1), and 0, 15, 30, or 45 min in the postanesthesia care unit (PACU) (T2-T5, respectively).
UNASSIGNED: There were 40 patients in group A, 41 patients in group B and 39 patients in group C. Patients in group B had significantly lower FLACC (Face, Legs, Activity, Cry, Consolability) pain scores at T2-T5 than those in group C (all p<0.05). Patients in group B had higher Ramsay Sedation Score at T2-T4 than those in group C (all p<0.05). The proportion of patients who received remedial analgesia in the PACU in group A (17.5%, p=0.008) and group B (9.8%, p<0.001) was significantly lower than that in group C (46.2%).
UNASSIGNED: Intravenous administration of nalbuphine 10 min before the end of adenotonsillectomy in children could decrease pain intensity and increase sedation levels during the recovery period with the reduction of remedial analgesia in the PACU.Trial registration number ChiCTR2200060118.
UNASSIGNED: Patients with obstructive sleep apnea syndrome scheduled for adenotonsillectomy were randomly divided into group A (patients received intravenous nalbuphine 0.2 mg/kg before anesthesia induction), group B (patients received intravenous nalbuphine 0.2 mg/kg 10 min before the end of surgery), and group C (patients did not receive nalbuphine injection). The time points for measuring outcomes were before anesthesia induction (T0), extubation (T1), and 0, 15, 30, or 45 min in the postanesthesia care unit (PACU) (T2-T5, respectively).
UNASSIGNED: There were 40 patients in group A, 41 patients in group B and 39 patients in group C. Patients in group B had significantly lower FLACC (Face, Legs, Activity, Cry, Consolability) pain scores at T2-T5 than those in group C (all p<0.05). Patients in group B had higher Ramsay Sedation Score at T2-T4 than those in group C (all p<0.05). The proportion of patients who received remedial analgesia in the PACU in group A (17.5%, p=0.008) and group B (9.8%, p<0.001) was significantly lower than that in group C (46.2%).
UNASSIGNED: Intravenous administration of nalbuphine 10 min before the end of adenotonsillectomy in children could decrease pain intensity and increase sedation levels during the recovery period with the reduction of remedial analgesia in the PACU.Trial registration number ChiCTR2200060118.
摘要：
■比较不同时间点静脉注射纳布啡对腺样体切除患儿术后镇痛和镇静的疗效。
■将进行腺样体扁桃体切除术的阻塞性睡眠呼吸暂停综合征患者随机分为A组（患者在麻醉诱导前静脉注射纳布啡0.2mg/kg），B组（患者在手术结束前10分钟静脉注射纳布啡0.2mg/kg），和C组（患者未接受纳布啡注射）。测量结果的时间点是麻醉诱导前（T0），拔管（T1），以及在麻醉后护理单元（PACU）中的0、15、30或45分钟（分别为T2-T5）。
■A组40例,B组41例，C组39例。B组患者FLACC明显降低(Face,腿,活动,哭吧,Consolability)疼痛评分在T2-T5时均优于C组(均p<0.05)。B组患者T2-T4时Ramsay镇静评分高于C组(均P<0.05)。A组PACU中接受补救镇痛的患者比例（17.5％，p=0.008)和B组(9.8%，p<0.001)显著低于C组(46.2%)。
■在儿童腺样体扁桃体切除术结束前10分钟静脉注射纳布啡可以降低疼痛强度，并在恢复期增加镇静水平，减少PACU的补救镇痛。试验注册号ChiCTR2200060118。
■将进行腺样体扁桃体切除术的阻塞性睡眠呼吸暂停综合征患者随机分为A组（患者在麻醉诱导前静脉注射纳布啡0.2mg/kg），B组（患者在手术结束前10分钟静脉注射纳布啡0.2mg/kg），和C组（患者未接受纳布啡注射）。测量结果的时间点是麻醉诱导前（T0），拔管（T1），以及在麻醉后护理单元（PACU）中的0、15、30或45分钟（分别为T2-T5）。
■A组40例,B组41例，C组39例。B组患者FLACC明显降低(Face,腿,活动,哭吧,Consolability)疼痛评分在T2-T5时均优于C组(均p<0.05)。B组患者T2-T4时Ramsay镇静评分高于C组(均P<0.05)。A组PACU中接受补救镇痛的患者比例（17.5％，p=0.008)和B组(9.8%，p<0.001)显著低于C组(46.2%)。
■在儿童腺样体扁桃体切除术结束前10分钟静脉注射纳布啡可以降低疼痛强度，并在恢复期增加镇静水平，减少PACU的补救镇痛。试验注册号ChiCTR2200060118。
